SCHEMBL20906131

SCHEMBL20906131

CCOC(=O)c1cc2c(Br)cc(C)cc2s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN2 P17706 2/20 0.49
KDM4E B2RXH2 3/20 0.41
TSHR P16473 2/20 0.41
HSD17B10 Q99714 1/20 0.41
JAK2 O60674 1/20 0.41
JAK1 P23458 1/20 0.41
TYK2 P29597 1/20 0.41
JAK3 P52333 1/20 0.41
MAPT P10636 7/20 0.40
GAA P10253 2/20 0.40
ALDH1A1 P00352 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
HPGD P15428 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
STING1 Q86WV6 2/20 0.39
MEN1 O00255 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26622018 0.86 PTPN2 (0.47) PTPN2KDM4ETSHRHSD17B10JAK2
SCHEMBL829006 0.85 CSNK2A2 (0.46) PTPN2KDM4EHSD17B10MAPTALDH1A1
SCHEMBL17080891 0.81 SLC9A1 (0.53) PTPN2KDM4ETSHRHSD17B10JAK2
SCHEMBL30430905 0.80 ICAM1 (0.51) PTPN2KDM4EICAM1SELE
SCHEMBL17080828 0.80 ICAM1 (0.51) PTPN2KDM4EICAM1SELE
SCHEMBL20906130 0.80 DAO (0.43) PTPN2KDM4EMAPTALDH1A1HDAC3
SCHEMBL25809967 0.78 PTPN2 (0.48) PTPN2KDM4ETSHRHSD17B10JAK2
SCHEMBL18069891 0.78 PTPN2 (0.48) PTPN2KDM4ETSHRHSD17B10JAK2
SCHEMBL30640482 0.77 MAPT (0.49) PTPN2KDM4ETSHRHSD17B10JAK2
SCHEMBL26621986 0.77 MAPT (0.49) PTPN2KDM4ETSHRHSD17B10JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023214325-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AND USES THEREOF AS TET2 INHIBITORS NOVARTIS AG (CH) 2023-11-09 WO disclosed
EP-3344604-B1 CARBOXY SUBSTITUTED (HETERO) AROMATIC RING DERIVATIVES AND PREPARATION METHOD AND USES THEREOF SUNSHINE LAKE PHARMA CO LTD (CN) 2020-11-04 EP disclosed
CN-106478500-B Carboxylic acid substituted (hetero) aromatic ring derivatives, and preparation method and application thereof 广东东阳光药业有限公司 2020-02-11 CN disclosed
US-10266496-B2 Carboxy substituted (hetero) aromatic ring derivatives and preparation method and uses thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2019-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10266496-B2 Carboxy substituted (hetero) aromatic ring derivatives and preparation method and uses thereof XDH, ABCG2, SLC7A1 PTPN2 2255/4885KDM4E 2400/4885TSHR 3794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.